The Australian Patent Registrar has granted the Company a patent for the use of inhaled Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases, such as AADT, COPD, CF, tuberculosis and more.
The Patent's title is:
"ALPHA 1 ANTITRYPSIN FOR TREATING EXACERBATION EPISODES OF PULMONARY DISEASES"